203 related articles for article (PubMed ID: 24163303)
1. Autologous dendritic cell based adoptive immunotherapy of patients with colorectal cancer-A phase I-II study.
Hunyadi J; András C; Szabó I; Szántó J; Szluha K; Sipka S; Kovács P; Kiss A; Szegedi G; Altorjay I; Sápy P; Antal-Szalmás P; Tóth L; Fazekas G; Rajnavölgyi É
Pathol Oncol Res; 2014 Apr; 20(2):357-65. PubMed ID: 24163303
[TBL] [Abstract][Full Text] [Related]
2. Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells.
Babatz J; Röllig C; Löbel B; Folprecht G; Haack M; Günther H; Köhne CH; Ehninger G; Schmitz M; Bornhäuser M
Cancer Immunol Immunother; 2006 Mar; 55(3):268-76. PubMed ID: 16034561
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients.
Lesterhuis WJ; De Vries IJ; Schreibelt G; Schuurhuis DH; Aarntzen EH; De Boer A; Scharenborg NM; Van De Rakt M; Hesselink EJ; Figdor CG; Adema GJ; Punt CJ
Anticancer Res; 2010 Dec; 30(12):5091-7. PubMed ID: 21187495
[TBL] [Abstract][Full Text] [Related]
4. Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-antigen positive tumors.
Tamir A; Basagila E; Kagahzian A; Jiao L; Jensen S; Nicholls J; Tate P; Stamp G; Farzaneh F; Harrison P; Stauss H; George AJ; Habib N; Lechler RI; Lombardi G
Cancer Immunol Immunother; 2007 Dec; 56(12):2003-16. PubMed ID: 17333181
[TBL] [Abstract][Full Text] [Related]
5. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides.
Kavanagh B; Ko A; Venook A; Margolin K; Zeh H; Lotze M; Schillinger B; Liu W; Lu Y; Mitsky P; Schilling M; Bercovici N; Loudovaris M; Guillermo R; Lee SM; Bender J; Mills B; Fong L
J Immunother; 2007 Oct; 30(7):762-72. PubMed ID: 17893568
[TBL] [Abstract][Full Text] [Related]
6. Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides.
Liu KJ; Wang CC; Chen LT; Cheng AL; Lin DT; Wu YC; Yu WL; Hung YM; Yang HY; Juang SH; Whang-Peng J
Clin Cancer Res; 2004 Apr; 10(8):2645-51. PubMed ID: 15102666
[TBL] [Abstract][Full Text] [Related]
7. A phase I clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatment.
Liu KJ; Chao TY; Chang JY; Cheng AL; Ch'ang HJ; Kao WY; Wu YC; Yu WL; Chung TR; Whang-Peng J
J Biomed Sci; 2016 Aug; 23(1):64. PubMed ID: 27558635
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G
Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414
[TBL] [Abstract][Full Text] [Related]
9. In vitro induction of carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses.
Cho HI; Kim HJ; Oh ST; Kim TG
Vaccine; 2003 Dec; 22(2):224-36. PubMed ID: 14615150
[TBL] [Abstract][Full Text] [Related]
10. Oncolysate-loaded Escherichia coli bacterial ghosts enhance the stimulatory capacity of human dendritic cells.
Michalek J; Hezova R; Turanek-Knötigova P; Gabkova J; Strioga M; Lubitz W; Kudela P
Cancer Immunol Immunother; 2017 Feb; 66(2):149-159. PubMed ID: 27864613
[TBL] [Abstract][Full Text] [Related]
11. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
12. The optimal interval for dendritic cell vaccination following adoptive T cell transfer is important for boosting potent anti-tumor immunity.
Park MY; Kim CH; Sohn HJ; Oh ST; Kim SG; Kim TG
Vaccine; 2007 Oct; 25(42):7322-30. PubMed ID: 17889413
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive immunological analyses of colorectal cancer patients in the phase I/II study of quickly matured dendritic cell vaccine pulsed with carcinoembryonic antigen peptide.
Sakakibara M; Kanto T; Hayakawa M; Kuroda S; Miyatake H; Itose I; Miyazaki M; Kakita N; Higashitani K; Matsubara T; Hiramatsu N; Kasahara A; Takehara T; Hayashi N
Cancer Immunol Immunother; 2011 Nov; 60(11):1565-75. PubMed ID: 21681375
[TBL] [Abstract][Full Text] [Related]
14. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients.
Hobo W; Strobbe L; Maas F; Fredrix H; Greupink-Draaisma A; Esendam B; de Witte T; Preijers F; Levenga H; van Rees B; Raymakers R; Schaap N; Dolstra H
Cancer Immunol Immunother; 2013 Aug; 62(8):1381-92. PubMed ID: 23728352
[TBL] [Abstract][Full Text] [Related]
16. Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests.
Lesterhuis WJ; de Vries IJ; Schuurhuis DH; Boullart AC; Jacobs JF; de Boer AJ; Scharenborg NM; Brouwer HM; van de Rakt MW; Figdor CG; Ruers TJ; Adema GJ; Punt CJ
Ann Oncol; 2006 Jun; 17(6):974-80. PubMed ID: 16600979
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives.
Morisaki T; Matsumoto K; Onishi H; Kuroki H; Baba E; Tasaki A; Kubo M; Nakamura M; Inaba S; Yamaguchi K; Tanaka M; Katano M
Hum Cell; 2003 Dec; 16(4):175-82. PubMed ID: 15147037
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules.
Morse MA; Clay TM; Hobeika AC; Osada T; Khan S; Chui S; Niedzwiecki D; Panicali D; Schlom J; Lyerly HK
Clin Cancer Res; 2005 Apr; 11(8):3017-24. PubMed ID: 15837756
[TBL] [Abstract][Full Text] [Related]
19. Induction of antigen-specific CD4- and CD8-mediated T-cell responses by fusions of autologous dendritic cells and metastatic colorectal cancer cells.
Koido S; Hara E; Torii A; Homma S; Toyama Y; Kawahara H; Ogawa M; Watanabe M; Yanaga K; Fujise K; Gong J; Toda G
Int J Cancer; 2005 Nov; 117(4):587-95. PubMed ID: 15945098
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
